MX2022015645A - Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes. - Google Patents

Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes.

Info

Publication number
MX2022015645A
MX2022015645A MX2022015645A MX2022015645A MX2022015645A MX 2022015645 A MX2022015645 A MX 2022015645A MX 2022015645 A MX2022015645 A MX 2022015645A MX 2022015645 A MX2022015645 A MX 2022015645A MX 2022015645 A MX2022015645 A MX 2022015645A
Authority
MX
Mexico
Prior art keywords
dosage forms
enterokine
gelling agents
pharmaceutical compositions
combination
Prior art date
Application number
MX2022015645A
Other languages
English (en)
Inventor
Steffen- Sebastian Bolz
Kai Deusch
Original Assignee
Aphaia Ip Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphaia Ip Ag filed Critical Aphaia Ip Ag
Publication of MX2022015645A publication Critical patent/MX2022015645A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas y artículos farmacéuticos que comprenden esas composiciones, donde las composiciones comprenden múltiples formas de dosificación cada una de las cuales comprende un núcleo y un revestimiento entérico, donde el núcleo comprende al menos un compuesto que estimula las células enteroendocrinas para liberar al menos una enterocina, donde el tamaño de las formas de dosificación, con respecto a la dimensión más grande de las formas de dosificación, proporciona la entrada de las formas de dosificación en el intestino de un sujeto independientemente de los mecanismos de vaciado gástrico y, donde la composición comprende además uno o más agentes gelificantes. La invención también se relaciona con el tratamiento o prevención de condiciones sensibles a la estimulación de la libración de enterocinasa por las células enteroendocrinas.
MX2022015645A 2020-06-10 2020-06-10 Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes. MX2022015645A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/066149 WO2021249641A1 (en) 2020-06-10 2020-06-10 Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents

Publications (1)

Publication Number Publication Date
MX2022015645A true MX2022015645A (es) 2023-03-21

Family

ID=71094332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015645A MX2022015645A (es) 2020-06-10 2020-06-10 Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes.

Country Status (13)

Country Link
US (1) US20230233471A1 (es)
EP (1) EP4164592A1 (es)
JP (1) JP2023537461A (es)
KR (1) KR20230040984A (es)
CN (1) CN116096352A (es)
AU (1) AU2020452539A1 (es)
BR (1) BR112022025220A2 (es)
CA (1) CA3182019A1 (es)
CO (1) CO2022018623A2 (es)
IL (1) IL298948A (es)
MX (1) MX2022015645A (es)
WO (1) WO2021249641A1 (es)
ZA (1) ZA202213412B (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322697A (en) 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US20140294951A1 (en) 2011-10-26 2014-10-02 Joseph M. Fayad Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
JP6253991B2 (ja) 2011-03-02 2017-12-27 ジェローム シェンターク， 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
JP5226097B2 (ja) * 2011-03-30 2013-07-03 株式会社ファンケル サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料
SI2887925T1 (sl) * 2012-08-27 2017-06-30 Evonik Roehm Gmbh Na želodčne tekočine odporen farmacevtski ali nutracevtski sestavek z odpornostjo na vpliv etanola
CN107405310A (zh) * 2014-12-15 2017-11-28 安纳生物科技有限公司 耐胃微胶囊及其在刺激哺乳动物内回肠glp‑1释放的用途
US20210205341A1 (en) * 2016-01-26 2021-07-08 Nestec S.A. Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
AU2019232145A1 (en) * 2018-03-07 2020-10-01 Teagasc - The Agriculture And Food Development Authority A composition for type II diabetics and for use in providing sustained energy release over time

Also Published As

Publication number Publication date
EP4164592A1 (en) 2023-04-19
KR20230040984A (ko) 2023-03-23
US20230233471A1 (en) 2023-07-27
WO2021249641A1 (en) 2021-12-16
CO2022018623A2 (es) 2023-03-07
CA3182019A1 (en) 2021-12-16
BR112022025220A2 (pt) 2023-03-07
CN116096352A (zh) 2023-05-09
IL298948A (en) 2023-02-01
JP2023537461A (ja) 2023-09-01
AU2020452539A1 (en) 2023-02-02
ZA202213412B (en) 2023-07-26

Similar Documents

Publication Publication Date Title
BRPI0403935A (pt) Formas de dosagem de azitromicina com efeitos colaterais reduzidos
BR112015023747A2 (pt) métodos para tratar inflamação, doenças autoimunes e dor
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
ITMI972788A1 (it) Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
MY155299A (en) Oral dosage composition
IN2014MN00139A (es)
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
MX2021011982A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
TR201819940T4 (tr) Enflamatuar bağırsak hastalığının tedavisi için yöntemler ve bileşimler.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
CA2632207C (en) Use of calcitonin for the treatment of ra
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2010009848A (es) Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
MX2019015733A (es) Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.
MX2022015645A (es) Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes.
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
TN2010000013A1 (en) Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
MD3422G2 (ro) Procedeu de profilaxie şi tratament al knemidocoptozei galinaceelor
WO2016091805A3 (de) Naloxon-monopräparat und mehrschichttablette
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
MX2018013070A (es) Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.